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Abstract
Biomolecular screening research frequently searches for the chemical compounds that are most 
likely to make a biochemical or cell-based assay system produce a strong continuous response. 
Several doses are tested with each compound and it is assumed that, if there is a dose-response 
relationship, the relationship follows a monotonic curve, usually a version of the median-effect 
equation. However, the null hypothesis of no relationship cannot be statistically tested using this 
equation. We used a linearized version of this equation to define a measure of pharmacological 
effect size, and use this measure to rank the investigated compounds in order of their overall 
capability to produce strong responses. The null hypothesis that none of the examined doses of a 
particular compound produced a strong response can be tested with this approach. The proposed 
approach is based on a new statistical model of the important concept of response detection limit, 
a concept that is usually neglected in the analysis of dose-response data with continuous 
responses. The methodology is illustrated with data from a study searching for compounds that 
neutralize the infection by a human immunodeficiency virus of brain glioblastoma cells.
Keywords
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1. Introduction
The goal of many biomolecular screenings in pharmaceutical research is to select from a set 
of chemical compounds a subset of compounds that modulate a biochemical or cell-based 
system. Compounds of interest will make the system produce a continuous response that 
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desirably will have a value higher than a prespecified minimum Rmin (or, in some cases, 
lower than a prespecified maximum Rmax), if the response were ideally measured without 
error. An example of response that desirably should be higher than a prespecified Rmin is the 
percent increase in the number of cancer cells that are killed after a certain time of exposure 
to a compound, relative to the number of cells that die after spending the same time in the 
absence of the compound; or the percent reduction in the amount of infection of a target cell 
by a virus which is observed after certain time of exposure to a compound, relative to the 
amount of infection after the same time in the absence of the compound. The value of Rmin 
is chosen so that responses higher than that value are considered pharmacologically or 
biologically important. An example of a response in which a maximum response Rmax is 
desirable is the percent increase in the number of non-cancerous cells that are killed after 
exposure to a potentially anti-cancer agent, relative to no exposure.
In the experiments modeled in this article, the effect of each of m compounds on a 
continuous bioassay response is investigated, and the same n compound doses D1 < D2 < … 
< Dn are tested with each of the m compounds. Here, Rij represents the observed response to 
dose Di of compound j, i = 1, …, n, j = 1, …, m, and the letter R will generically represent 
the response to a dose D if this response were ideally measured without error. That is, R is 
the "true" or "adjusted-for-error" response, as opposed to the observed response Rij which is 
obtained through an experimental procedure that usually involves error. In other words, Rij is 
a particular measure of a theoretical dimension R.
Here, we are interested in responses R that theoretically are numbers between 0 and 100 
inclusive. In practice, however, a particular measure Rij of R may be outside the interval [0, 
100]. For instance, suppose that R is the percent reduction of a virus infection of a cell 
system, produced by a chemical compound, and that the magnitude of a luminescent signal 
measures the extent of the virus infection. In this case, R can be measured by computing the 
percent reduction in luminescent signal with respect to the signal of a control bioassay. 
Because of unavoidable experimental errors, this percent reduction may be < 0 for some 
compounds, even under the theoretical assumption that none of the investigated compounds 
may increase the extent of the infection or the assumption that the assay may not detect an 
infection increase.
Ideally, a particular compound should be selected for future investigations if, after adjusting 
for experimental error, at least one of its investigated doses yields R > Rmin (or R < Rmax), 
where Rmin > 0 (or Rmax < 100). However, since many of the examined compounds may 
satisfy this condition, and only a few compounds can be used in future investigations to 
minimize project costs, researchers must rank the compounds in order of their overall 
capability to cause the cell system to produce R > Rmin (or R < Rmax) within the dose range 
tested. Once the compounds are ranked, the compounds with the highest capabilities would 
be selected for future investigations.
As described below, the non-linear regression methodology traditionally used in dose 
response analyses, which fits a parametric curve to the pairs (D1, R1j), …, (Dn, Rnj), is 
frequently not suitable for conducting this ranking, and never can be used for testing the null 
hypothesis that none of the n examined doses of a particular compound produced a true 
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response higher (or lower) than the reference response Rmin (or Rmax) (versus the alternative 
hypothesis that at least one of the examined doses produced a true response higher than the 
reference response). The objective of this article is to suggest methodology for conducting 
this ranking and testing.
The most popular approach to comparing the effects of two or more compounds on a 
continuous response R relies on estimating for each compound the dose D that makes R = 
50%, symbolized here as D(50). (Depending on the type of response, this dose is called IC50, 
ED50, LD50, etc.) This approach assumes that, for each compound and the dose range tested 
[D1, Dn], the relationship between a dose D and the true response R follows a monotonic 
dose-response curve. The most frequently used model for this curve is the median-effect 
equation
(1)
which includes as particular cases the well-known Michaelis-Menten and Hill (Goutelle 
2008) equations, as well as the Henderson-Hasselbalch and Scatchard equations (Chou 
2006). This equation has parameters w ∈ ℝ and D(50) > 0 that are frequently estimated for 
each compound from observed responses by using non-linear regression with additive errors 
and least squares estimation.
Admitting that the D(50) measure is widely used in both pharmacological and biological 
research, this measure has a number of limitations that hinder its applications to compound 
ranking and statistical testing in biomolecular screening (Diaz et al. 2013). The limitations 
essentially stem from the fact that the D(50) has to be computed under the assumption of the 
existence of a dose-response effect and, therefore, the D(50) cannot be used to statistically 
test the null hypothesis of no dose-response effect for the compound, or the more general 
null hypothesis that no investigated compound dose has an important effect on the response. 
Moreover, the D(50) measure cannot be reliably computed in many cases (Diaz et al. 2013). 
An elaboration of this and other limitations is provided in Section 2.
A central premise of this article is that the research question of interest in a biomolecular 
screening is not whether there is a monotonic relationship between response and dose for a 
particular chemical compound, or whether a parametric curve can be fitted to the 
compound’s dose-response pairs of points, but whether one of the investigated doses really 
produces a response of importance, where a response is considered important if it is > Rmin 
(or < Rmax) after adjusting for experimental error. The question of whether some dose 
outside the examined dose range [D1, Dn] can produce an important response cannot be 
answered with the types of experiment that are studied in this article, and answering this 
question is not an objective of this article.
In this article, we show how some further elaborations of equation (1) provide an approach 
that can be used for compound ranking and compound-effect testing, which does not have 
the mentioned limitations of a direct application of this equation. This approach is based on 
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a logit transformation of this equation which has been used by other authors for theoretical 
purposes or for estimating w and D(50) with a limited number of doses (for instance, with 
only two doses) (Chou 2006), and on a new statistical model of the important concept of 
response detection limit, a concept that, unfortunately, is usually neglected in dose-response 
analyses with continuous responses.
The potential of the logit transformation of equation (1) for improving decision making in 
pharmacological and biological research does not seem to have been fully appreciated. As 
elaborated in Section 3, this potential stems from the fact that the logit transformation 
induces a family of dose-response curves that is much larger than the family of curves 
represented by equation (1). The logit transformation, however, has a limitation of its own: it 
cannot be applied to observed responses outside the interval (0, 100). To address this issue, 
this article posits that observed responses that are negative or close to 0 should be considered 
as mostly generated by a mechanism that is different from (and independent of) the 
mechanism producing the relationship represented by equation (1). This different 
mechanism occurs because negative, null or close-to-zero observations are likely measures 
of true responses that are below the response detection limit, and the experimental 
conditions cannot correctly quantify such responses. These observations, however, are not 
excluded from analyses because doing so would bias the decision against the null hypothesis 
of no compound effects. Instead, they are used to estimate the detection limit through the 
model proposed in Section 5. The estimated detection limit and the number of negative, null 
or close-tozero responses are then used to constraint the estimation of the parameters of the 
linear regression based on the logit-transformed data, as described in Section 9.
Section 2 describes limitations of nonlinear regression and the D(50) in the context of 
ranking and statistical testing of chemical compound effects. Section 3 gives a mathematical 
motivation for using a logit-linearized form of the median effect equation in statistical 
testing of compound effects. Sections 4, 5 and 6 introduce the proposed model. Sections 7 
and 8 introduce a measure of pharmacological importance of a compound and the null 
hypothesis of no importance. Section 9 explains a method to estimate the measure of 
pharmacological importance of a compound, and Section 10 a method to examine the 
statistical significance of the estimate. Sections 11 and 12 describe a method of estimating 
the detection limit for the pharmacological response. Section 13 and 14 present an 
application to the search for compounds that neutralize HIV infection. A discussion is in 
Section 15.
2. Limitations of nonlinear regression approaches and the D(50)
In equation (1), the theoretical response R is a strictly increasing function of D when w > 0, 
and strictly decreasing when w < 0. When w = 0, R = 50 regardless of the dose D and the 
value of D(50) (Figure 1); thus, D(50) is unambiguously defined only if w ≠ 0, that is, only 
when R is a strictly monotonic function of D. This fact imposes three major limitations. 
First, equation (1) by itself does not allow modeling data showing a nearly constant 
relationship between R and D that may be of pharmacological interest, even if such data is 
produced by a compound satisfying equation (1) for a dose range wider than the dose range 
tested. Such relationships may occur, for instance, when all tested doses produce 
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substantially strong responses but the examined dose range is not wide enough to detect an 
appreciable increase (or a decrease) in response with dose.
Figure 2 illustrates some problems arising in such situation. The solid line is a plot of 
equation (1) with D(50) = 3 and w = 0.7. The five points are dose-response pairs that were 
simulated with these parameter values and a normal random noise with mean 0 and variance 
4. The five points may give the impression of a nearly constant dose-response relationship.
When equation (1) was fitted to the five points in Figure 2 through nonlinear least squares, 
misleading parameter estimates were obtained, 0.05309 and 0.2077 for D(50) and w, 
respectively. The dashed line represents the fitted equation. Moreover, data points like the 
ones illustrated usually produce convergence problems in least squares algorithms when 
attempting to fit equation (1), because this equation does not include parameters accounting 
for constant responses other than R = 50 and the parameters of equation (1) are not 
identifiable for a constant response of R = 50. Thus, some important compounds may not be 
identified in a biomolecular screening if these algorithms are applied without additional 
visual inspection, and the D(50) measure cannot even be obtained for some compounds. 
Moreover, visual inspections may be impractical if the number of examined compounds is 
relatively large.
Analogous problems occur when small doses are tested. In this case, it is not unusual that 
the observed dose-response curve of a compound j does not reach a clear plateau, even if the 
compound has a dose-response effect; as a result, no reliable estimator for the D(50) of 
compound j can be obtained by fitting equation (1) to the pairs (D1, R1j), …, (Dn, Rnj), and 
there are even cases in which no D(50) measure can be obtained (Diaz et al. 2013).
Second, the D(50) measure, and indeed equation (1) alone, cannot be used to statistically test 
the null hypothesis that the investigated doses of the compound do not have a differential 
effect on the bioassay response, nor the null hypothesis that none of the investigated doses of 
the compound have an effect on the response (Diaz et al. 2013). The reason is that the 
parameter space of equation (1), namely {(w, D(50)) ∈ ℝ2; D(50) > 0}, does not include the 
case in which R = constant (or R ≈ constant) for all D. In other words, since equation (1) can 
be fitted to observed responses only under the assumption that there is a strictly monotonic 
relationship between dose and true response, the null hypothesis of no relationship cannot be 
tested.
Third, also because of the limitations of the parameter space of equation (1), this equation 
(and therefore the D(50)) cannot be used by itself to model the important case in which R 
takes on a nearly constant but high (or low) value within the dose range [D1, D2], which may 
occur if this range is not wide enough (Figure 2). In plain words, constant responses cannot 
be modeled with equation (1). This is a limitation because excluding from future analyses a 
compound that showed a constant response solely because its data does not conform with 
equation (1) may introduce a decision error. In fact, the constant response value to the 
compound may be substantially larger than Rmin (or lower than Rmax) and, therefore, the 
compound may be a good candidate for future analyses. Because of these limitations, 
automated decision rules that distinguish whether (and to what extent) a compound affects 
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the investigated response cannot be designed by using D(50) measurements (Diaz et al. 2013) 
and, in fact, cannot be designed by using nonlinear regression theory solely based on 
equation (1).
3. Rationale of the proposed approach to hypothesis testing
To motivate our proposed approach, note that equation (1) can be transformed into
(2)
provided that 0 < R < 100, where T is the logit transformation defined as T(x) = log(x/(100 − 
x)), 0 < x < 100 (Chou 2006). Assuming that equation (1) represents well the dose-response 
relationship for a compound j, equation (2) could be used to estimate the D(50) of compound 
j by fitting a simple linear regression model to the points (log (Di), T(Rij)), i = 1, …, n (Chou 
2006). However, this would work well only if the range [D1, Dn] of tested doses is 
sufficiently wide.
Nonetheless, even when D(50) cannot be reliably estimated, the slope and intercept of the 
estimated linear relationship between T(R) and log(D) have information about the 
magnitude of the responses to the doses in the dose range tested. Thus, if we focus only on 
the slope and intercept, we see that equation (2) can be rewritten as
(3)
with a, b ∈ ℝ.
Note that, although equation (1) can be algebraically transformed into equation (3), these 
two equations are not algebraically equivalent, unless both w, a ≠ 0, because there are no 
restrictions on the values of a and b in equation (3). Specifically, by letting a = w and b = −w 
log (D(50)), we see that any non-constant dose-response relationship satisfied by equation (1) 
is also satisfied by equation (3). However, whereas equation (3) is satisfied by all possible 
constant relationships of the form R ≡ r for all D and some r ∈ (0, 100) [use a = 0 and b = 
T(r)], the only constant relationship satisfied by equation (1) is the relationship R ≡ 50 
which occurs when w = 0 (although, in this case, D(50) is not identifiable).
In summary, the family of relationships between D and R that is represented by equation (3) 
is larger than the family represented by equation (1). In addition to strictly monotonic 
relationships, equation (3) includes essentially all constant relationships, which makes 
equation (3) useful to model relationships that may be pharmacologically or biologically 
important but are empirically nearly-constant or constant within the investigated dose range 
(like that suggested by the five points represented in Figure 2). Even more, in contrast to 
equation (1), the parameter space of equation (3) contains a null subspace representing the 
null hypothesis of no important pharmacological effects (see Section 8).
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4. The concept of detection limit and other preliminary concepts
Our model of the dose-response pairs (Di, Rij), i = 1, …, n, j = 1, …, m, essentially assumes 
that equation (3) is satisfied by all m examined compounds and doses within the dose-range 
tested, and that each compound has its own values of a and b. But, the model also postulates 
the existence of a constant number θ, 0 < θ < 100, such that, if R < θ, then R is unreliably 
measured. The parameter θ is called the detection limit for R. If the dose Di of compound j 
produced a true response R < θ, then the measure Rij of R is not considered informative 
about the parameters of equation (3). These ideas are formally stated in Section 5.
Note that the detection limit θ is postulated to be a constant of the entire set of experiments, 
that is, θ does not depend on i or j. The detection limit θ is interpreted as a response value 
below which the biologist accepts that the available experimental setup and instrumentation 
does not allow measuring the response R with confidence. Thus, the particular value of θ is 
a consequence of the technology and knowledge used to measure R, and it is not an intrinsic 
property of any of the examined chemical compounds or of the biological system to which 
they are applied.
The proposed model is applicable only if it can be reliably assumed either that a ≥ 0 for all 
compounds tested, or a ≤ 0 for all compounds tested. We stress that the situation a = 0 is 
included in these two cases, that is, constant responses are accepted as possible in our 
formulation. For convenience, the methodology will be described only for the case a ≥ 0. In 
this case, we do not expect that any of the tested compounds will exhibit a strictly decreasing 
monotonic relationship between response and dose within the investigated dose range, nor 
an umbrella-shape or other non-monotonic relationship, and we search for compounds 
producing R > Rmin. The assumption that a ≥ 0 for all compounds is reasonably fulfilled by 
the data used to illustrate the proposed methodology (Section 13).
The case a ≤ 0 can be handled analogously to the case a ≥ 0 by transforming the response R 
into 100 − R. Since the usual goal of a biomolecular screening under the case a ≤ 0 is to find 
compounds producing R < Rmax, the transformation Rmin = T (100 − Rmax) is also needed 
and, using these two transformations, all that will be described for the case a ≥ 0 applies 
verbatim to the case a ≤ 0.
In what follows, we say that a random variable X has a scaled beta distribution with 
parameters α > 0, β > 0 and θ > 0, if the probability density function (pdf) of X is
(4)
That is, fX is the pdf of a beta random variable with parameters α and β that has been 
multiplied by θ. If X has pdf (4), then we say that the distribution of X is Sbeta(α, β, θ).
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Let θ be the detection limit for R. The model postulates that, for the entire set of 
experiments, there exist constant numbers α > 0, β > 0 and γ > 0 in addition to θ, and that 
for each compound j, with j = 1, …, m, there exist numbers aj ≥ 0 and bj ∈ ℝ, such that
• Model Assumption 1: For all i = 1, …, n and j = 1, …, m, if aj log (Di)+bj ≥ Tθ, 
then P (Rij ≤ 0) = 0 and E[T(Rij)] = aj log (Di) + bj, where Tθ denotes T(θ).
• Model Assumption 2: If I is the set of all pairs (i, j) in the Cartesian product {1, 
…, n} × {1, …, m} satisfying aj log (Di) + bj < Tθ, and if (i, j) ∈ I, there exists 
an unobserved random variable  producing values in the interval (0, θ) such 
that the conditional distribution of  given the event {0 < Rij < 100} is Sbeta(α, 
β, θ).
• Model Assumption 3: If (i, j) ∈ I, the conditional distribution of T(Rij) given both 
 and the event {0 < Rij < 100} is normal with mean T(r) and variance γ2.
• Model Assumption 4: If (i, j) ∈ I, then all observed responses Rij with (i, j) ∈ I 
are mutually independent and identically distributed.
• Model Assumption 5: P (Rij ≥ 100) = 0 for all i = 1, …, n and j = 1, …, m.
• Model Assumption 6: For a particular compound j, all observations T(Rij) with 
(i, j) ∉ I are normally distributed with variance , and are mutually independent.
6. Explanation of model assumptions
As mentioned in Section 4, the detection limit θ is not a characteristic of a particular 
compound but a parameter of the entire set of experiments which depends on the 
experimental and analytical methods used to measure R. In contrast, aj and bj are parameters 
whose values reflect the effect of compound j on the response R. The assumption aj ≥ 0 for 
all j is applicable when strictly monotonically decreasing relationships are not considered 
possible for the compounds examined.
Model Assumptions 2–4 are informally interpreted as follows: attempting to measure R 
when R is below the detection limit produces an unwanted artifact R* generated by an Sbeta 
(α, β, θ) distribution (Model Assumption 2). In that situation, Rij is measuring the artifact 
R*, not R (Model Assumption 3). As a consequence, when R < θ, Rij does not have any 
information about aj or bj (Model Assumption 4).
Define , i = 1, …, n, and . By Model Assumption 1, if 
, then
(5)
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As described in Section 8,  contains all the information we need to statistically test the 
effect of compound j on the response R in the dose range examined; thus, the statistical test 
proposed in this article focuses on this parameter. However, both aj and  are needed to 
measure the size of this effect, as described in Section 7.
According to Model Assumption 4, if  for some i and j, then the 
observed response Rij to dose Di of compound j has little or unreliable information on aj and 
 because, in that case, even if aj ≠ 0 or , the distribution of Rij does not depend on aj 
or . In other words, true responses lower than the detection limit are unreliably measured.
For a particular compound j, we say that the true response produced by a dose Di is below 
the detection limit θ, or that Di produced a true response below the detection limit, if and 
only if . In this case, Assumption 4 implies that Rij is uninformative, and 
therefore, that Rij should not be used to estimate aj or . In practice, Model Assumption 5 
means that no observed response is ≥ 100, which is the case in many applications searching 
for compounds that increase the value of a response, and usually occurs when relatively 
small compound doses are tested in a biomolecular screening.
7. A measure of the effect size of a chemical compound on a bioassay 
response
In the following, we assume that Rmin > θ and denote Tmin = T (Rmin). Suppose that we are 
investigating whether at least one of the n tested doses of compound j can produce, after 
adjusting for response measurement errors, an important response (i.e. a "true" response 
higher than Rmin). More precisely, we want to know if  for some i, and 
therefore, if the true response to Di is pharmacologically important (that is, by Model 
Assumption 1, if E [T(Rij)] > Tmin).
To measure the pharmacological importance of the effect of compound j on the response R, 
we propose computing the effect size
(6)
where [z]+ = max{z, 0}. Note that . Therefore, the integration region in formula 
(6), the closed interval  is the same as the interval . As a 
consequence, this integration region covers the entire range of tested doses, and only this 
range. Thus, since Ej is dependent on the particular dose range tested, that is, on the interval 
[D1, Dn], a comparison of the Ej values of two different compounds is appropriate only if the 
same dose range was used for examining the two compounds. The higher Ej is, the stronger 
are the responses to compound j. A convenient computational formula for Ej is presented in 
Appendix 1.
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When Ej > 0, Ej can be geometrically represented in an xy-coordinate system as that portion 
of the area between the lines  and y = Tmin that is relevant to the dose range 
tested. This interpretation of Ej is illustrated in Figure 3 (A–E), in which the subscript j is 
dropped for clarity. Also, Ej = 0 essentially means that no true response R to compound j is 
higher than Rmin within the dose range tested (Figure 3, F–H).
8. The null hypothesis of no important effect of a compound
Since, in general, Ej ≥ 0, the null hypothesis of no important effects of compound j on the 
response R within the dose range tested can be stated as H0: Ej = 0, and we should test this 
hypothesis against the alternative H1: Ej > 0. But, since we are assuming that aj ≥ 0 for all j, 
the null hypothesis H0: Ej = 0 is equivalent to , and the alternative H1: Ej > 0 is 
equivalent to . (See Appendix 2 for a proof.)
Provided that at least one true response to compound j is above the detection limit, the 
maximum possible E [T(Rij)] in the investigated dose range is . Therefore, H0 may be 
paraphrased as "After adjusting for measurement errors, no response to compound j is above 
Rmin", and H1 as "At least one dose of compound j produces a response above Rmin".
9. Estimation of the effect size Ej
To estimate Ej for a particular compound j, aj and  need to be estimated first. This section 
describes an approach to estimating aj,  and Ej. When there are reasons to believe that 
some of the true responses R produced by compound j are below the detection limit θ, the 
value of θ needs to be known or estimated before using this approach. Section 12 describes 
an approach to estimating θ.
Denote yij = T(Rij) and . Let 1 ≤ k < n and assume that the lowest k doses of 
compound j produced true responses below the detection limit θ but the remaining doses do 
not. That is, assume  for i ≤ k, and  for i > k.
As estimators of aj and , we propose using the values of aj and  that minimize the sum of 
squares function
(7)
subject to the k constraints , i = 1, …, k. Since xh < xi for all h < i, and we are 
assuming aj ≥ 0, these k constraints are equivalent to the unique constraint
(8)
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Thus, only one constraint is needed to perform the minimization of the sum of squares in 
(7). The obtained estimators of aj and  are denoted âj and .
If no i is assumed to satisfy  for compound j, we define k = 0 and estimate aj 
and  by minimizing (7) without any constraint. In this case, the obtained estimators are just 
ordinary least squares estimators that can be produced with any linear regression software, 
and are still denoted by âj and . When k ≥ 1, nonlinear regression software can be used to 
compute âj and  as explained in Appendix 3.
In any case, Ej is estimated with . Although we are assuming that aj ≥ 0, 
we do not impose the additional constraint aj ≥ 0 when minimizing (7). This is not a 
problem, and it is even advantageous, for three reasons. First, a goal of computing âj and 
is to compute Êj, which is well defined for any âj, even a negative one. Second, minimizing 
 with respect to  under constraint (8) is equivalent to minimizing 
 with respect to , where A = {(a, b*) ∈ ℝ2; axk + b* < Tθ}. Since A is 
open and convex, standard theory of least squares estimation guarantees that, when aj ≥ 0 
and under very general conditions on the distribution of yij for i ≥ k + 1, âj and  are 
consistent estimators of aj and  as n − k → ∞ (Shao 2003). As a consequence, Êj is a 
consistent estimator of Ej under aj ≥ 0.
Third, an advantage of not enforcing the additional constraint aj ≥ 0 in the minimization of 
(7) is that the adequacy of the assumption aj ≥ 0 can be examined by testing the null 
hypothesis that aj ≥ 0 versus the alternative aj < 0 by using a standard Wald test based on âj 
and its standard error. This would not be possible if the additional constraint aj ≥ 0 were 
imposed because in such case âj would never be negative.
10. Testing the null hypothesis of no important effect for a particular 
compound
To test H0: Ej = 0 versus H1: Ej > 0 we use Model Assumptions 1 and 6. Under these 
assumptions, the theory of least squares estimation allows showing that an approximate 
estimate of the standard error of  denoted by , can be computed as the square root of 
the first diagonal element of the estimated variance-covariance matrix
(9)
and  (Shao 2003). Now define k = n if all n doses of compound j 
produced true responses below the detection limit θ. To test H0 at a significance level α, we 
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follow the following decision rule: if n − k − 2 ≥ 1, use the t statistic 
and reject H0 in favor of H1 if τj > tp,α, where tp,α is a right-tail critical value of a central t 
distribution with p = n − k − 2 degrees of freedom; and if n − k − 2 < 1, do not reject H0. If 
desired, a p-value can be computed and corrected for multiple comparisons when n − k − 2 ≥ 
1.
11. Practical considerations in the estimation of aj and 
In some practical situations, the biologist who conducted the experiments can provide a 
working value for the detection limit θ, which may be suggested by his/her experience and 
knowledge. With this provided value, aj and  can be estimated for a particular compound j 
by using the methodology described in Section 9.
If a value for θ is not available from previous experience, θ can be estimated by using the 
model and approach proposed in Section 12. In any case, a question that needs to be 
answered before estimating aj and  is how to decide whether or not a particular observed 
response Rij was produced under the inequality , that is, whether the 
measured response is unreliable.
Biologists usually assume that an observed response less than or equal to 0 reflects the fact 
that the true response lies below the detection limit, because experimental setup and 
instrumentation frequently do not allow measuring very small responses with acceptable 
precision. Guided by practical considerations, we incorporate this biologist’s assumption 
into our approach by assuming the following:
• Working Assumption: Rij ≤ 0 implies  for all h ≤ i, even if 
Rhj > 0 for some h < i.
In other words, since aj ≥ 0 for all j, we also assume that, if Rij ≤ 0, then dose Dh of 
compound j has produced a true response below the detection limit for all h ≤ i. Thus, if Rij 
≤ 0, Rhj is not used directly to estimate the parameters in equation (5) when h ≤ i, although 
the information that  is incorporated into the estimation approach 
described in Section 9 and Appendix 3.
Our approach, however, does not exclude other possible rules that the biologist or 
researchers may agree on to incorporate in an automated algorithm that decides whether or 
not a particular compound dose has produced a true response below the detection limit. Note 
that the Working Assumption can be viewed as a consequence of Model Assumption 1, 
because, by the latter, P (Rij ≤ 0) > 0 implies .
12. Estimation of the detection limit
If previous experience or knowledge does not provide a reasonable value for the detection 
limit θ, Model Assumptions 2–4 can be used to estimate θ, as described in this Section.
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Model Assumptions 2 and 3 imply that if dose Di of compound j produced a true response 
below the detection limit and 0 < Rij < 100, then the unconditional distribution of the 
observed transformed response T(Rij) is a mixture of normal distributions with a scaled beta 
as the mixing distribution, where the scaled beta is defined in Section 4. Specifically, it can 
be shown that the unconditional pdf of T(Rij), is
(10)
where −∞ < z < ∞, with parameters α > 0, β > 0, γ2 > 0 and 0 < θ < 100. Note that, 
consistent with Model Assumption 4, the pdf fT does not depend on particular aj or 
parameters and depends only on global parameters α, β, θ and γ2.
Although the parameter of interest is θ, we estimate α, β, θ and γ2 simultaneously through 
maximum likelihood methodology by using the transformed observations T(Rij) satisfying 
both (i, j) ∈ I and 0 < Rij <100, which, by Model Assumptions 2, 3 and 4, constitute a 
random sample from fT.
For practical purposes, the parameters in the pdf in (10) will be estimated by using the 
transformed observations T(Rhj) that satisfy both Rhj > 0 and Rij ≤ 0 for some i > h. By the 
Working Assumption in Section 11 and Model Assumptions 1–4, the collection of logit-
transformed observations satisfying these two conditions can be treated as a random sample 
from the pdf fT in (10). Once parameter estimates for α, β, θ and γ2 are obtained, the 
goodness of the fit of pdf (10) is examined by using a quantile-quantile (Q-Q) plot (Coles 
2001).
The above approach to estimating the parameters in (10) additionally assumes that the 
detection limit θ is not substantially greater than 0, because we are not including 
transformed observations T(Rhj) such that Rij > 0 for all i ≥ h in the random sample from fT. 
This approach, however, will not bias the maximum likelihood estimator of θ towards 0 if 
this additional assumption about θ is not correct. The reason is that, by Model Assumption 
4, even if θ is substantially large and other observed responses Rij with (i, j) ∈ I are not 
included in the sample, the observations T(Rhj) satisfying both Rhj > 0 and Rij ≤ 0 for some i 
> h still can be considered as independent observations from the pdf in (10); therefore, the 
maximum likelihood estimator of θ will still enjoy its good usual properties.
If θ is relatively large, however, the proposed approach has two limitations: 1) the number of 
observations T(Rhj) satisfying both Rhj > 0 and Rij ≤ 0 for some i > h may not be large 
enough to produce a reliable maximum likelihood estimator of θ; and 2) some observations 
T(Rhj) such that Rij > 0 for all i ≥ h may be rightfully considered as observations from the 
pdf in (10), but we do not know how to identify them and, more importantly, these 
unidentified observations may adversely affect the estimation of aj and  because they will 
be wrongfully treated as informative about aj and  when implementing the least squares 
estimation approach described in Section 9.
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We stress that the support of fT is the set (−∞, ∞), not the set (0, θ). Thus, in principle, if R 
< θ, it is possible that Rij > θ and, therefore, that the estimated value of θ be smaller than 
some of the observations used to estimate θ.
As an additional justification of the proposed approach to estimating θ, observe that a 
consequence of the Working Assumption in Section 11 is that if Rhj>0 but Rij ≤ 0 for some i 
> h, then Rhj must contain information about the detection limit θ. For instance, if Rhj were 
too high, say 70%, since Dh < Di and aj ≥ 0, we would suspect that the experimental setup 
does not allow measuring strong responses with confidence, and therefore, that the detection 
limit is far from zero. Our approach extracts this information in order to produce an estimate 
of θ.
In summary, transformed observations T(Rhj) that satisfy both Rhj> 0 and Rij ≤ 0 for some i 
> h are viewed as constituting a random sample from a probability distribution that has θ as 
one of its parameters. A maximum likelihood estimate of θ is thus obtained with these 
observations.
13. Application: Neutralization of virus infection
Here, the proposed methodology is applied to data from experiments whose goal was to 
quantify the extent to which each of 62 compounds neutralizes the infection of the sensitive 
human brain glioblastoma cell line U87+T4+CCR5 by the JR-FL strain of human 
immunodeficiency virus, described in Krachmarov et al. (2001). Each compound was tested 
at 7 doses, namely 0.2382, 0.4763, 0.9527, 1.9053, 3.6916, 7.5023 and 15.0045 µM. The 62 
compounds were selected from a library of 5,152 small-molecule compounds that were 
previously screened for their effect on virus infection at a single compound dose of 10 µM 
each.
The extent of the infection neutralization was indicated by a decrease in luminescent signal 
from a luciferase cell-based assay system, the magnitude of the luminescent signal reflecting 
the strength of the infection. The response R to a particular dose is a percent neutralization 
of virus infection that was defined as the percentage of luminescence that was decreased 
after the system was exposed to the compound for 72 hours relative to a control. The higher 
the percent neutralization, the greater the inhibition of virus infection of the U87+T4+CCR5 
cells by the compound. Doses of added compounds that neutralized 50–100% of baseline 
luminescence were searched for. Compounds exhibiting such doses would be considered of 
pharmacological interest for future studies. Thus, we will use Rmin = 50%.
Here, the effect size Ej will be used as a measure of the overall ability of compound j to 
neutralize the viral infection, j = 1, …, 62; this measure combines the information produced 
by the 7 tested doses and treats any error-adjusted neutralization lower than 50% as 
unimportant. Biochemical methods are described in Appendix 4.
Some negative or zero percent neutralizations occurred when the final luminescent signal in 
the presence of the compound was equal to or greater than that produced by virus infection 
in the absence of compound. None of the 62 compounds produced a neutralization of Rij ≥ 
100% at the tested doses.
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To estimate the detection limit θ through maximum likelihood estimation of the parameters 
of pdf (10), the commands NIntegrate and NMaximize of the software Mathematica were 
used (Wolfram Research, Inc.). Table 1 shows the observations Rkj used to estimate these 
parameters, which satisfied both Rkj>0 and Rij ≤ 0 for some i > k. Parameter estimates for 
the pdf (10) were α̂ = 35.5616, β̂ = 4.34595, γ̂ = 0.899033 and γ̂ = 4.42281. Figure 4 shows 
a Q-Q plot built with these estimates, which suggests the adequacy of the proposed detection 
limit model for the neutralization data in Table 1. Thus, a detection limit of about 4.42% 
seems to be appropriate for the neutralization response.
The approach described in Sections 9–10 was applied to the neutralization data, using θ = 
4.42%. Compound effect sizes (the Ej’s) and their significances were computed by using 
Rmin = 50%. A Stata program was written to implement the model (Baum 2009). (The 
program is available from the corresponding author on request.) Stata’s nonlinear regression 
command (nl) was used for those compounds with k ≥ 1 (Appendix 3). Table 2 shows 
compound effect sizes Ej and the estimates of aj and  for each compound for which these 
parameters could be estimated (that is, compounds with n − k ≥ 3). In Table 2, compounds 
were ranked according to estimated effect size. The six compounds with the largest 
pharmacological effect sizes were KU0104459 (Ej = 11.858), KU0101338 (11.592), 
KU0102728 (11.155), KU0104328 (10.562), KU0104458 (10.250) and KU0102846 (8.235); 
these effect sizes were significantly larger than 0. Out of those compounds for which n − k ≥ 
3, three had an Ej = 0 (KU0102611, KU0044662 and KU0101694), and 8 had a 
nonsignificant Ej > 0.
A total of 32 compounds had a significant effect size (Table 2). This apparently large 
number should not come as a surprise, since the 62 compounds examined in these analyses 
had been previously selected as the most promising compounds from an initial high 
throughput screening that explored 5,152 compounds. That is, 32 compounds constitute just 
0.62% of the initially explored library of compounds. Also, observing 32 “significant” 
compounds out of 62 should not be interpreted as an indication of an inflated Type I error 
for an individual statistical test. In fact, for k = 0, standard theory of least squares guarantees 
that the probability of Type I error of the test proposed in Section 10 is always ≤ α when the 
observations T(Rij) are normally distributed.
For the case k > 0, we performed a simulation study using a nominal α = 0.05, which 
showed that the probability of Type I error for an individual test was not larger than α for 
fixed k = 1, 2, 3, 4. Observe that, strictly speaking, for a particular compound, k is a random 
variable. Thus, the conditional probability of Type I error given k was ≤ α for all k = 0, 1, 2, 
3, 4. But, a compound was not concluded to be an effective compound when k = 5, 6, 7, 
where k = 7 if R7,j = 0; that is, for each of these other k’s, the conditional probability of Type 
I error given k was 0. All this implies that the unconditional probability of Type I error was 
≤ α, as desired. The methods and results of this simulation study are available from the 
corresponding author on request.
All âj’s in Table 2 are non-negative, which suggests that our key assumption that aj ≥ 0 for 
all j may be valid for these particular infection neutralization experiments. Should one 
compound exhibit an âj < 0, a Wald test of the null hypothesis H0: aj ≥ 0 versus the 
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alternative H1: aj < 0 could be conducted in order to examine the adequacy of this 
assumption for the compound.
Observe from Table 2 that there is a trend for high values of k to be associated with small 
effect sizes Ej. This was expected because Rmin > θ, and therefore, if a large number of 
tested doses of a particular compound produced true responses below the detection limit 
then we can infer that the compound did not have important pharmacological effects in the 
dose range tested (i.e., did not produce R > Rmin for those doses). The effect size Ej just 
captures this lack of important effects.
14. Further comments about the estimation of the detection limit for 
infection neutralization response
Table 3 illustrates responses from some compounds. The compounds in Rows 1 and 2 of 
Table 3 did not produce any non-positive response, so simple linear regression was used to 
estimate their parameters aj and  after logit-transforming their responses. Rows 3–14 of 
Table 3 show the data from some compounds that produced some true responses below the 
detection limit according to the Working Assumption in Section 11.
The compound in Row 3 of Table 3 produced a non-positive response at dose D1. One may 
be tempted to estimate aj and  for this compound by using simple linear regression without 
constraints with only the information from doses Di, i ≥ 2. However, such approach 
disregards the knowledge that D1 is producing a response below the detection limit, 
information that may be useful to improve our estimates of aj and . Besides, ignoring this 
information may bias our conclusions about this compound against the null hypothesis H0: 
Ej = 0, as explained in the Discussion. Rows 4–6 of Table 3 also show compounds for which 
some of the smallest doses produced responses below the detection limit. However, no 
compound in rows 3–6 provided positive responses usable for estimating the detection limit 
θ.
Row 7 in Table 3 shows an extreme case that helps to motivate the Working Assumption in 
Section 11. For the compound in this row, R1,j > 0%. However, Rij ≤ 0 for all i ≥ 2. Since we 
are assuming that aj ≥ 0, there is not doubt that R1,j = 7.13% contains no information about 
aj and  and that the true response produced by D1 should be below the detection limit θ. 
However, R1,j is valuable in that, if Model Assumptions 2–4 in Section 5 are correct, R1,j 
carries information about the true value of θ, and therefore, can be used to estimate θ. 
Similar comments about the observed response R3,j = 6.33% to dose D3 of the compound in 
Row 8 can be made. In this case, the idea that R3,j carries information about the detection 
limit is suggested by the fact that all doses higher than D3 produced non-positive observed 
responses.
To further illustrate, by the Working Assumption, the following observations were used to 
estimate θ : R1,j = 4.45% for the compound in Row 9 of Table 3; R2,j = 3.81% (Row 10); 
R1,j = 17.66 and R2,j = 9.58% (Row 11); R1,j = 0.70, R2,j = 17.34 and R3,j = 1.88% (Row 
12); and R1,j = 7.84 and R3,j = 2.37% (Row 13).
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The compound in Row 14 produced non-positive observed responses at all tested doses. This 
strongly suggests that, for this compound, the investigated doses did not have any influence 
on the investigated neutralization response and always produced true responses below the 
detection limit. Moreover, no observations provided by this compound can be used to 
estimate θ nor to estimate aj and .
15. Discussion
From a practical point of view, the most important product of this research is that we are 
able to produce tables like Table 2 that include measures of effect sizes that allow comparing 
the pharmacological importance of chemical compounds, and p-values that allow testing the 
significance of these effect sizes.
A major disadvantage of a direct application of the median effect equation in (1) is that this 
equation does not allow statistically testing the null hypothesis of no effect of the chemical 
compound on the pharmacological response. Nonlinear regression approaches based on 
equation (1) alone cannot be used to examine this hypothesis, because equation (1) 
implicitly assumes that there is a dose-response efffect. In other words, the problem is that 
the parameter space of equation (1) does not include the possibility of no dose-response 
effect. In fact, any statistical test procedure based on a parametric model requires that the 
parameter space contains a null space representing the null hypothesis (Shao 2003). In 
contrast, in addition to essentially containing all dose-response relationships represented by 
equation (1), equation (3) allows testing a null hypothesis of no effect.
An added advantage of equation (3) is that dose response relationships that are nearly 
constant within the investigated dose range can be easily handled with this equation, and a 
measure of pharmacological effect size (Ej) based on equation (3) can be defined for (and 
used to compare) many types of relationships. In particular, Ej allows comparing the effect 
of a compound producing a nearly constant relationship with the effect of a compound 
producing a relationship represented by the median effect equation. In contrast, a direct use 
of equation (1) creates problems when analyzing nearly constant relationships, as illustrated 
in Figure 2, because equation (1) does not include parameters representing constant 
relationships. As mentioned in the introduction, in a biomolecular screening, non-negligible 
almost-constant relationships can be found which are produced by compounds with 
pharmacologically important dose-response effects. This may occur, for instance, if the 
investigated dose range was not wide enough for those compounds.
Our approach also introduces a formal and precise way of incorporating the important 
concept of response detection limit in the analysis of dose-response data with continuous 
responses, a concept that is usually neglected in these types of analysis. A criterion is also 
suggested for the identification of responses that have taken on values below the detection 
limit. As described in Section 12, although this criterion will generally produce a reliable 
estimator of θ, the criterion may not be entirely adequate for estimating Ej when θ is 
considerably larger than 0. The proposed approach is in general adequate only if θ can be 
reasonably assumed to be relatively small.
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The assumption that the detection limit θ is not large may be reasonable in many 
biomolecular screenings, and this assumption seems to be reasonably satisfied by the data 
analyzed in Section 13. However, further research is needed in order to refine the approach 
proposed in Section 12, and/or propose more approaches amenable to automation. The 
experience and knowledge of the biologists and pharmacologists involved in measuring 
continuous responses in cell-based assays are undoubtedly crucial to developing, in future 
research, further criteria for the identification of data that can be used to estimate the 
detection limit, especially in situations in which the detection limit is suspected to be large.
Observed null or negative responses cannot be ignored when estimating the parameters of 
the linearized form (3), which involves a logit transformation T that is undefined for non-
positive responses. In fact, when k ≥ 1, minimizing the sum of squares (7) subject to 
constraint (8) produces a larger estimate of the error variance σ2 than without the constraint. 
This can be seen by noting that if âu,j and  are the unconstrained least squares estimators 
of aj and , then
But, . Thus, excluding from the analysis responses below the 
detection limit such as those corresponding to observed null or negative responses, and 
fitting a simple linear regression model to the remaining (Di, T(Rij)) pairs, underestimates 
the standard error of the least squares estimate of  and, therefore, biases conclusions 
against the null hypothesis H0: Ej = 0 and increases type II error (because the standard error 
of  is in the denominator of the statistic τj defined in Section 10).
In particular, simply put, since observed non-positive responses are evidence in favor of the 
null hypothesis of no effects, these responses should not be excluded from the data when 
fitting the linearized form (3) of the median effect equation. An approach that appropriately 
handles these responses, such as the one proposed in this paper, should be followed instead.
Moreover, by Model Assumption 4, observed responses obtained when the true response is 
below the detection limit are independent across (and within) compounds. As a 
consequence, the presence of many ineffective compounds in the compound sample that is 
used to estimate θ will not bias θ̂. In fact, the presence of such compounds may even be 
beneficial to the estimation of θ because the more ineffective compounds are there, the 
higher the chance of obtaining true responses with low values, including true responses 
below the detection limit.
It should be noted that, although the transformation T(R) = log(R/(100 − R)) assumes that 0 
and 100 are low and upper bounds of R, respectively, the use of equation (3) and the 
methodology proposed in this article do not require that the scatterplot of the actual dose-
response data of a particular compound exhibits a plateau of height 100 at its right side or a 
plain of height 0 at its left side. Even if the observed maximum response of a particular 
compound is farther down from 100 or its observed minimum is farther up from 0, the 
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transformation T(R) and the proposed effect size measure and statistical test are still 
applicable, provided that at least three different doses producing true responses above the 
detection limit are tested and at least three different observed responses are obtained, and 
provided equation (3) is valid.
Alternatively, if there are reasons to believe that the dose response curve follows a sigmoidal 
shape with a minimum response λ1 > 0 and a maximum λ2 < 100, say, where λ1 and λ2 are 
known values, the transformation R’ = {(R − λ1) / (λ2 − λ1)}×100 should be applied before 
using the proposed methodology. That is, R’ and T(R’) should be used instead of R and 
T(R), respectively. However, the effect sizes from a set of compounds can be compared only 
if the values of both λ1 and λ2 are the same across all compounds.
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Appendix 1
A computational formula for Ej




Figure 3 shows graphical representations of Ej made with formulas (11)–(13).
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Appendix 2. Proof of the equivalence of H0: Ej = 0 and  when aj ≥ 0
Suppose Ej = 0. Then,  for all x in the closed interval , 
because  is a continuous function of x. Thus,  for all x 
in . In particular, using x = 0, we obtain .
Now suppose . For all x in , we have that x ≤ 0 and, therefore, 
 because aj ≥ 0. Thus, for all x in ; 
this implies Ej = 0.
Appendix 3
Computation of âj and b̂j
The minimization of (7) subject to constraint (8) can be carried out with any nonlinear 
regression software. In this computational approach, we use the fact that if εij is a random 
error, then the linear regression model , i = k + 1, …, n, accompanied with 
constraint (8), is algebraically equivalent to the nonlinear regression model
(14)
where aj and γj are unknown parameters that need to be estimated and satisfy 
. The reason the two models are equivalent is that the constraint 
 is equivalent to eγj > 0, which is always true. When n − k ≥ 3, estimates âj and 
γ̂j for aj and γj can be obtained by fitting model (14) to the pairs (xi, yij), i = k + 1, …, n, 
using least squares. Then, the constrained least squares estimate of  is computed as 
. We recommend using this approach for computing the point 
constrained estimates âj and , as well as , but  should 
be computed separately and  should be obtained from matrix (9).
Alternative methods for constrained minimizations are also available in statistical and non-
statistical software. For instance, the command NMinimize of the package Mathematica 
allows implementing constrained minimizations through global optimization algorithms 
(Wolfram Research, Inc.), although more programming effort is needed to implement this 
command for the dose-response analyses proposed here than if using standard nonlinear 
regression software.
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The percent neutralization response R was measured through a single-cycle infectivity assay 
using virions generated from the Env-defective luciferase-expressing HIVNL4-3 genome, 
pseudotyped with molecularly cloned HIV Env, as previously described (Pinter et al. 2004). 
Pseudotyped virions in culture supernatants from transfected 293T cells were incubated with 
serial dilutions of MAbs or polyclonal sera from HIV-infected subjects for 1 h at 37°C, and 
were then added in the presence of Polybrene (10 g/ml) to U87-T4-CCR5 target cells plated 
out in 384-well plates. Luciferase activity was determined 72 hours postinfection using 
assay reagents from Promega (SteadyGlo) and a microtiter plate luminometer (Tecan 
Safire2).
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Plot of the median effect equation (1) for different values of w and D(50).
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Illustration of a problem that may occur when the range of investigated doses includes doses 
that produce strong responses but is not wide enough to represent the overall dose-response 
relationship.
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Illustration of five situations producing a compound effect size E > 0 (A–E), and three 
producing E = 0 (F–H) (continued). In A through E, the area of the region highlighted with 
vertical lines is equal to E. Referring to formulas (11)–(13), plot (A) corresponds to the case 
a > 0, b* > Tmin and ; in plot (B), a > 0, b* > 
Tmin, but ; (C) a = 0, yielding E > 0 because b* > 
Tmin; (D) a < 0,  and min {(Tmin − b*)/a, 0} = 0; (E) a < 0, 
 and min {(Tmin − b*)/ a, 0} = (Tmin − b*)/ a ; (F) a = 0, yielding E = 0 
because b* < Tmin ; (G) a > 0, b* < Tmin; (H) a < 0 and .
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Quantile-quantile (Q-Q) plot for model of detection limit estimated with virus-infection 
neutralization data. The points tend to align along a straight line with slope 1 and intercept 0, 
suggesting that pdf (10) is a reasonable model of the detection limit for percent 
neutralization responses, and therefore, that an estimated detection limit of 4.42% is 
reasonable for these responses. The Q-Q plot was made with 1 the points (F̂−1(i/m), T(i)), i = 
1, …, 21 − 1, where T(1) ≤ … ≤ T(21) are the order statistics of the 21 transformed responses 
in Table 1 which were used to estimate the parameters α, β, θ and γ2 of pdf (10), and F̂ is an 
estimate of the cumulative distribution function corresponding to this pdf, which was 
computed with the maximum-likelihood estimates of these parameters.
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Table 1
Observed percent neutralization responses used to estimate the detection limit θ. The compound concentration 
(dose) variable was not used in the estimation of the detection limit and is shown here only for reference. The 
estimated detection limit for the neutralization response was θ = 4.42%.
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